본문으로 건너뛰기
← 뒤로

Single-cell transcriptome profiling of post-treatment and treatment-naïve colorectal cancer: Insights into putative mechanisms of chemoresistance.

1/5 보강
Cancer letters 📖 저널 OA 19.1% 2023: 1/3 OA 2024: 6/34 OA 2025: 14/119 OA 2026: 50/210 OA 2023~2026 2026 Vol.636() p. 218127
Retraction 확인
출처

PICO 자동 추출 (휴리스틱, conf 2/4)

유사 논문
P · Population 대상 환자/모집단
추출되지 않음
I · Intervention 중재 / 시술
standard chemotherapy (comprising 14 responders and 6 progressors)
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
Progressor tumor cells also expressed two chemo-protective markers, MTRNR2L1 and CDX1, co-expressed with the stemness-related immune-checkpoint CD24. In summary, scRNA-seq reveals distinct prognostic markers and features underlying progression to chemotherapy in MSS CRC.

Puzanov GA, Astier C, Papakonstantinou D, Quiroga Londoño M, Blériot C, Yurchenko AA

📝 환자 설명용 한 줄

Drug resistance remains a major clinical challenge in the treatment of colorectal cancer (CRC) with conventional chemotherapy regimens.

이 논문을 인용하기

↓ .bib ↓ .ris
APA Puzanov GA, Astier C, et al. (2026). Single-cell transcriptome profiling of post-treatment and treatment-naïve colorectal cancer: Insights into putative mechanisms of chemoresistance.. Cancer letters, 636, 218127. https://doi.org/10.1016/j.canlet.2025.218127
MLA Puzanov GA, et al.. "Single-cell transcriptome profiling of post-treatment and treatment-naïve colorectal cancer: Insights into putative mechanisms of chemoresistance.." Cancer letters, vol. 636, 2026, pp. 218127.
PMID 41218746 ↗

Abstract

Drug resistance remains a major clinical challenge in the treatment of colorectal cancer (CRC) with conventional chemotherapy regimens. Analyzing post-treatment changes in tumor cells and the tumor microenvironment (TME) is essential to understanding resistance development. We analyzed single-cell RNA sequencing (scRNA-seq) data derived from 50 colorectal cancers (CRCs). This cohort included 30 treatment-naïve tumors (25 microsatellite stable (MSS) and five microsatellite unstable (MSI)) and 20 tumors that had previously received standard chemotherapy (comprising 14 responders and 6 progressors). Compared to MSS tumors, MSI tumors exhibited an immune-enriched tumor microenvironment (TME), marked by higher cytotoxic T cell activity and a less pronounced mesenchymal phenotype. Primary left-sided CRCs were associated with metastatic potential and depleted B cells. In post-treatment CRC, responders showed a high prevalence of a dendritic cell (DC) TME signature, which correlated with better survival in TCGA. Progressors showed TME enrichment of pericyte-like fibroblasts (associated with poor survival) and elevated exhausted CD8 T cells, suggesting a pro-inflammatory TME. Progressor tumor cells also expressed two chemo-protective markers, MTRNR2L1 and CDX1, co-expressed with the stemness-related immune-checkpoint CD24. In summary, scRNA-seq reveals distinct prognostic markers and features underlying progression to chemotherapy in MSS CRC.

🏷️ 키워드 / MeSH 📖 같은 키워드 OA만

🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반